Results 11 to 20 of about 846,625 (333)
Weighted Nash Inequalities [PDF]
Nash or Sobolev inequalities are known to be equivalent to ultracontractive properties of Markov semigroups, hence to uniform bounds on their kernel densities.
Bakry, Dominique +3 more
core +11 more sources
Secret contracting and Nash-in-Nash bargaining
In take-it-or-leave-it vertical contracting, an equilibrium with passive beliefs may fail to exist. We argue that this problem can be alleviated by tackling the contracting stage of the game through a cooperative approach. The outcome of the take-it-or-leave-it game then coincides with the limit of the cooperative solution when the bargaining power of ...
Bacchiega, Emanuele, Bonroy, Olivier
openaire +3 more sources
New instrumental learning occurs through an unexpected delivery of a rewarding stimulus or the withdrawal of a punishing stimulus. The authors show that D1 receptor-expressing medium spiny neurons (MSNs) in the anterior dorsolateral striatum encode newly
Alexander C. W. Smith +7 more
doaj +1 more source
Pleiotropic effects of ipragliflozin
Type 2 diabetes mellitus and its complications is a serious threat to the health and lives of the world's population. Among the causes of death in type 2 diabetes mellitus are both cardiovascular and non-vascular causes. Sodium-glucose cotransporter type
Nina A. Petunina +5 more
doaj +1 more source
Beyond Nash Bargaining Theory: The Nash Set [PDF]
zbMATH Open Web Interface contents unavailable due to conflicting licenses.
Serrano, Roberto, Shimomura, Ken-Ichi
openaire +3 more sources
Scramblases as Regulators of Autophagy and Lipid Homeostasis: Implications for NAFLD
Equilibration of phospholipids between the two monolayers of the lipid bilayer of cellular membranes is mediated by scramblases acting as phospholipid shuttling proteins that are critical for cellular function, particularly during inter-organelle contact.
Allen Chen, Wen-Xing Ding, Hong-Min Ni
doaj +1 more source
Effect of ipragliflozin on metabolic syndrome components and non-alcoholic fatty liver disease
Sodium-glucose cotransporter-2 inhibitors are the new drugs for the treatment of type 2 diabetes mellitus. Its mechanism of action is to increase the excretion of glucose in the urine due to inhibition of reabsorption in the proximal renal tubules, which
N. A. Petunina +2 more
doaj +1 more source
CXCR2 inhibition enables NASH-HCC immunotherapy
Objective Hepatocellular carcinoma (HCC) is increasingly associated with non-alcoholic steatohepatitis (NASH). HCC immunotherapy offers great promise; however, recent data suggests NASH-HCC may be less sensitive to conventional immune checkpoint ...
J. Leslie +45 more
semanticscholar +1 more source
Current treatment paradigms and emerging therapies for NAFLD/NASH.
Non-alcoholic fatty liver disease (NAFLD) is one the fastest emerging manifestations of the metabolic syndrome worldwide. Non-alcoholic steatohepatitis (NASH), the progressive form of NAFLD, may culminate into cirrhosis and hepatocellular cancer (HCC ...
Sana Raza +4 more
semanticscholar +1 more source

